Scancell stops dosing in long-term trial of cancer vaccine SCIB1

By Gareth Macdonald

- Last updated on GMT

Scancell: New SCIB1 supplies could be up to a year away. iStock/takahashi_kei
Scancell: New SCIB1 supplies could be up to a year away. iStock/takahashi_kei

Related tags Immune system

Scancell Holdings has stopped dosing in a long-term extension arm of a trial of its cancer vaccine SCIB1 after discovering the product is no longer within original specification.

The firm stopped administering the DNA cancer vaccine to the eight melanoma patients involved in the study arm last Friday. 

It said: “In discussion with the MHRA Clinical Trials Unit, and with patient safety of primary importance, the Company has concluded that it is no longer suitable for further use, although no new side effects have emerged.​”

The study – known as SCIB1-001​ – was initiated in 2010 by Scancell's CRO PharmaNet​ (which was acquired by inVentiv in 2011). The programme recruited 35 skin cancer patients at sites in the UK and was originally intended to last six months.

However, it was extended several times in response to “continuing encouraging results and an excellent side effect profile” ​according to Scancell, which pointed out that “as a result, some of the trial materials have now been stored for over 7 years​.”

More supplies

Scancell said it plans to make more SCIB1 which be provided to patients in the long term study arm and predicted that production would be complete in the next nine to 12 months.

The supplies will also be used in a new study examining the vaccine in combination with a checkpoint inhibitor.

The UK biotech said it has hired a contract manufacturing organisation (CMO) to produce SCIB1  on its behalf.

SCIB1 is a plasmid DNA that encodes a human antibody that express two cytotoxic T cell epitopes derived from the melanoma antigens: Tyrosinase-Related Protein 2 (TRP2) and gp100 plus two helper T cell epitopes.

After the vaccine is administered the antibody is expressed and then taken up by dendritic cells, resulting in the development of immune responses against tumour cells expressing the TRP2 and gp100 antigens.

Related news

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars